JPS62135499A - プラスモジウム　フアルシパルムの赤血球内侵入期に得られる該プラスモジウム　フアルシパルムの抗原と、該抗原の精製法と、該抗原および該抗原の抗体の投与量決定法と、該抗原を含むマラリア用ワクチン - Google Patents

プラスモジウム　フアルシパルムの赤血球内侵入期に得られる該プラスモジウム　フアルシパルムの抗原と、該抗原の精製法と、該抗原および該抗原の抗体の投与量決定法と、該抗原を含むマラリア用ワクチン

Info

Publication number: JPS62135499A
Authority: JP; Japan
Prior art keywords: antigen; culture medium; plasmodium falciparum; kda; protein
Prior art date: 1985-10-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP61256704A

Other languages

English (en)

Japanese (ja)

Inventor

アラン　ヴェルヌ

ジャン−フランソワ　デュブロメ

ベルナール　フォルティエ

パトリック　デルプラース

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ANSUCHI NATL de la SANTE E DE

ANSUCHI NATL de la SANTE E de la RECH MEDICAL ETAB PIYUBURITSUKU A KARAKUTEELE SCIENT E TEKUNOROJITSUKU

Original Assignee

ANSUCHI NATL de la SANTE E DE

ANSUCHI NATL de la SANTE E de la RECH MEDICAL ETAB PIYUBURITSUKU A KARAKUTEELE SCIENT E TEKUNOROJITSUKU

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-28

Filing date

1986-10-28

Publication date

1987-06-18

1986-10-28 Application filed by ANSUCHI NATL de la SANTE E DE, ANSUCHI NATL de la SANTE E de la RECH MEDICAL ETAB PIYUBURITSUKU A KARAKUTEELE SCIENT E TEKUNOROJITSUKU filed Critical ANSUCHI NATL de la SANTE E DE

1987-06-18 Publication of JPS62135499A publication Critical patent/JPS62135499A/ja

Status Pending legal-status Critical Current

Links

102000036639 antigens Human genes 0.000 title claims description 70
108091007433 antigens Proteins 0.000 title claims description 70
239000000427 antigen Substances 0.000 title claims description 68
238000000034 method Methods 0.000 title claims description 54
241000224016 Plasmodium Species 0.000 title description 9
238000000746 purification Methods 0.000 title description 9
229940124735 malaria vaccine Drugs 0.000 title 1
230000035515 penetration Effects 0.000 title 1
239000001963 growth medium Substances 0.000 claims description 78
241000223960 Plasmodium falciparum Species 0.000 claims description 52
210000003743 erythrocyte Anatomy 0.000 claims description 51
102000004169 proteins and genes Human genes 0.000 claims description 45
108090000623 proteins and genes Proteins 0.000 claims description 45
210000002966 serum Anatomy 0.000 claims description 42
244000045947 parasite Species 0.000 claims description 34
239000006228 supernatant Substances 0.000 claims description 23
201000004792 malaria Diseases 0.000 claims description 15
239000002243 precursor Substances 0.000 claims description 13
229960005486 vaccine Drugs 0.000 claims description 12
101800000116 Replicase small subunit Proteins 0.000 claims description 11
210000001563 schizont Anatomy 0.000 claims description 11
239000000243 solution Substances 0.000 claims description 11
102000004190 Enzymes Human genes 0.000 claims description 10
108090000790 Enzymes Proteins 0.000 claims description 10
244000005700 microbiome Species 0.000 claims description 10
230000009545 invasion Effects 0.000 claims description 9
238000001962 electrophoresis Methods 0.000 claims description 8
238000012360 testing method Methods 0.000 claims description 7
101710092702 47 kDa protein Proteins 0.000 claims description 6
238000006243 chemical reaction Methods 0.000 claims description 6
230000000694 effects Effects 0.000 claims description 6
210000003934 vacuole Anatomy 0.000 claims description 6
238000001042 affinity chromatography Methods 0.000 claims description 5
101710194912 18 kDa protein Proteins 0.000 claims description 4
101710124086 Envelope protein UL45 Proteins 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 4
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 4
230000003053 immunization Effects 0.000 claims description 4
230000001850 reproductive effect Effects 0.000 claims description 4
108060003951 Immunoglobulin Proteins 0.000 claims description 3
238000002649 immunization Methods 0.000 claims description 3
102000018358 immunoglobulin Human genes 0.000 claims description 3
230000003381 solubilizing effect Effects 0.000 claims description 3
230000003100 immobilizing effect Effects 0.000 claims description 2
230000007928 solubilization Effects 0.000 claims description 2
238000005063 solubilization Methods 0.000 claims description 2
239000003792 electrolyte Substances 0.000 claims 1
239000000644 isotonic solution Substances 0.000 claims 1
230000007115 recruitment Effects 0.000 claims 1
238000010790 dilution Methods 0.000 description 12
239000012895 dilution Substances 0.000 description 12
210000004408 hybridoma Anatomy 0.000 description 12
239000008363 phosphate buffer Substances 0.000 description 12
210000004027 cell Anatomy 0.000 description 11
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 10
238000002372 labelling Methods 0.000 description 10
210000003936 merozoite Anatomy 0.000 description 10
229930182817 methionine Natural products 0.000 description 10
201000010099 disease Diseases 0.000 description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
229920002684 Sepharose Polymers 0.000 description 8
239000000499 gel Substances 0.000 description 8
238000005406 washing Methods 0.000 description 8
230000003287 optical effect Effects 0.000 description 7
239000000284 extract Substances 0.000 description 6
238000005534 hematocrit Methods 0.000 description 6
238000001114 immunoprecipitation Methods 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 5
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000011534 incubation Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
238000002347 injection Methods 0.000 description 5
102000013415 peroxidase activity proteins Human genes 0.000 description 5
108040007629 peroxidase activity proteins Proteins 0.000 description 5
239000000047 product Substances 0.000 description 5
238000011282 treatment Methods 0.000 description 5
241000255925 Diptera Species 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
206010037660 Pyrexia Diseases 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000012228 culture supernatant Substances 0.000 description 4
230000000521 hyperimmunizing effect Effects 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
230000036039 immunity Effects 0.000 description 4
239000000463 material Substances 0.000 description 4
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 4
239000001397 quillaja saponaria molina bark Substances 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
229930182490 saponin Natural products 0.000 description 4
150000007949 saponins Chemical class 0.000 description 4
210000003046 sporozoite Anatomy 0.000 description 4
235000000385 Costus speciosus Nutrition 0.000 description 3
244000258136 Costus speciosus Species 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
241000282412 Homo Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
238000006911 enzymatic reaction Methods 0.000 description 3
238000003312 immunocapture Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
238000011002 quantification Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000283707 Capra Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
238000011088 calibration curve Methods 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000007865 diluting Methods 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
230000001360 synchronised effect Effects 0.000 description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
AKYHKWQPZHDOBW-UHFFFAOYSA-N (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol Chemical compound OS(O)(=O)=O.C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 AKYHKWQPZHDOBW-UHFFFAOYSA-N 0.000 description 1
LBSFSRMTJJPTCW-DSXUQNDKSA-N (r)-[(2s,4s,5r)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol;hydrochloride Chemical compound Cl.C([C@H]([C@H](C1)C=C)C2)CN1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LBSFSRMTJJPTCW-DSXUQNDKSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
206010003399 Arthropod bite Diseases 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
206010057248 Cell death Diseases 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
239000001576 FEMA 2977 Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
101100280646 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) fal-1 gene Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
101001002763 Plasmodium chabaudi Acidic phosphoprotein Proteins 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
244000309464 bull Species 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012136 culture method Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000000245 forearm Anatomy 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000002917 insecticide Substances 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000005497 microtitration Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000004848 nephelometry Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000006911 nucleation Effects 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000036281 parasite infection Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
210000004303 peritoneum Anatomy 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
229940093430 polyethylene glycol 1500 Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
229960003110 quinine sulfate Drugs 0.000 description 1
230000027756 respiratory electron transport chain Effects 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
238000009738 saturating Methods 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
229940054269 sodium pyruvate Drugs 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
241000894007 species Species 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
210000004215 spore Anatomy 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000002255 vaccination Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

JP61256704A 1985-10-28 1986-10-28 プラスモジウム　フアルシパルムの赤血球内侵入期に得られる該プラスモジウム　フアルシパルムの抗原と、該抗原の精製法と、該抗原および該抗原の抗体の投与量決定法と、該抗原を含むマラリア用ワクチン Pending JPS62135499A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8515986A FR2589062B1 (fr)	1985-10-28	1985-10-28	Antigenes obtenus a partir de la phase intraerythrocytaire de plasmodium falciparum, leur purification, leur dosage ainsi que celui de leurs anticorps, et vaccins contre le paludisme les renfermant
FR8515986		1985-10-28

Publications (1)

Publication Number	Publication Date
JPS62135499A true JPS62135499A (ja)	1987-06-18

Family

ID=9324269

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP61256704A Pending JPS62135499A (ja)	1985-10-28	1986-10-28	プラスモジウム　フアルシパルムの赤血球内侵入期に得られる該プラスモジウム　フアルシパルムの抗原と、該抗原の精製法と、該抗原および該抗原の抗体の投与量決定法と、該抗原を含むマラリア用ワクチン

Country Status (5)

Country	Link
EP (1)	EP0223665B1 (de)
JP (1)	JPS62135499A (de)
AT (1)	ATE70979T1 (de)
DE (1)	DE3683261D1 (de)
FR (1)	FR2589062B1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL83231A0 (en) *	1986-07-17	1987-12-31	Saramane Pty Ltd	Small molecular weight antigen of plasmodium falciparum,antibodies directed thereto,purification and detection of said antigen
IT1198233B (it) *	1986-12-23	1988-12-21	Eniricerche Spa	Metodo per la determinazione di anticorpi antisporozoita di p. falciparum nel sangue umano
US5231168A (en) *	1988-09-16	1993-07-27	Statens Seruminstitut	Malaria antigen
WO1990002811A1 (en) *	1988-09-16	1990-03-22	Statens Seruminstitut	A malaria antigen
AU5851390A (en) *	1989-06-19	1991-01-08	Statens Serum Institut	A malaria vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2099300B (en) *	1981-05-21	1985-02-27	Wellcome Found	Antigens from parasites of the genus plasmodium
IL64878A (en) *	1982-01-27	1986-01-31	Yissum Res Dev Co	Method for detection of and determination of malaria antibodies and malaria antigens in human blood
WO1984002471A1 (fr) *	1982-12-27	1984-07-05	Pasteur Institut	Fractions polypeptides induisant des anticorps protecteurs contre les parasites de la malaria et composition immunogene les contenant
US4767622A (en) *	1983-08-19	1988-08-30	University Of Illinois	Method and materials for development of immunological responses protective against malarial infection
FR2550942B1 (fr) *	1983-08-25	1986-04-25	Ambroise Thomas Pierre	Vaccin contre le paludisme et procede de preparation de ce vaccin

1985
- 1985-10-28 FR FR8515986A patent/FR2589062B1/fr not_active Expired - Lifetime
1986
- 1986-10-16 AT AT86402314T patent/ATE70979T1/de active
- 1986-10-16 DE DE8686402314T patent/DE3683261D1/de not_active Expired - Lifetime
- 1986-10-16 EP EP86402314A patent/EP0223665B1/de not_active Expired - Lifetime
- 1986-10-28 JP JP61256704A patent/JPS62135499A/ja active Pending

Also Published As

Publication number	Publication date
EP0223665B1 (de)	1992-01-02
FR2589062A1 (fr)	1987-04-30
ATE70979T1 (de)	1992-01-15
EP0223665A1 (de)	1987-05-27
DE3683261D1 (de)	1992-02-13
FR2589062B1 (fr)	1990-05-04

Publication	Publication Date	Title
Cossio et al.	1974	Chagasic cardiopathy: demonstration of a serum gamma globulin factor which reacts with endocardium and vascular structures
US5001225A (en)	1991-03-19	Monoclonal antibodies to a pan-malarial antigen
Shepherd et al.	1987	Specific and cross-reactive antigens of Echinococcus granulosus hydatid cyst fluid
Cronlund et al.	1976	Fibrinopeptide A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosus.
Araujo et al.	1980	Antigenemia in recently acquired acute toxoplasmosis
Naz et al.	1989	Sperm antibodies in vasectomized men and their effects on fertilization
Naz et al.	1990	Antibodies to sperm surface fertilization antigen (FA‐1): Their specificities and site of interaction with sperm in male genital tract
Marsh et al.	1986	Parasite-infected-cell-agglutination and indirect immunofluorescence assays for detection of human serum antibodies bound to antigens on Plasmodium falciparum-infected erythrocytes
Kahl et al.	1982	Variable and common antigens of Babesia bovis parasites differing in strain and virulence.
Sánchez et al.	1993	Quantification of low levels of rainbow trout immunoglobulin by enzyme immunoassay using two monoclonal antibodies
El Amin et al.	1986	Characterization of the humoral immune response in Sudanese leishmaniasis: specific antibody detected by class-and subclass-specific reagents
Huot et al.	1989	Protection against nerve toxicity by monoclonal antibodies to the sodium channel blocker tetrodotoxin.
JP2853877B2 (ja)	1999-02-03	プロタミン反応性ＩｇＭ抗体
JPS62135499A (ja)	1987-06-18	プラスモジウム　フアルシパルムの赤血球内侵入期に得られる該プラスモジウム　フアルシパルムの抗原と、該抗原の精製法と、該抗原および該抗原の抗体の投与量決定法と、該抗原を含むマラリア用ワクチン
Howard et al.	1987	Antibodies to tubulin in patients with parasitic infections
Perrudet-Badoux et al.	1969	On the mechanism ofrosette'formation in human and experimental thyroiditis
Chang-Yuan et al.	1992	A Mab-based ELISA for detecting circulating antigen in CSF of patients with neurocysticercosis
Sadun et al.	1968	Demonstration of homocytotropic reaginlike antibodies in mice and rabbits infected with Trichinella spiralis
US5614194A (en)	1997-03-25	Protective peptide antigen
Desai et al.	1994	Detection of autoantibodies to neural antigens in the CSF of Japanese encephalitis patients and correlation of findings with the outcome
Vora et al.	1981	Production and characterization of monoclonal antibodies to the subunits of human phosphofructokinase: new tools for the immunochemical and genetic analyses of isozymes
CA1335082C (en)	1995-04-04	Monoclonal antibody recognizing -hanp and a reagent for immunoassay of -hanp
Kanai et al.	1978	Induction of specific antibodies to poly (ADP–ribose) in rabbits by double-stranded RNA, poly (A)· poly (U)
Chiang et al.	1984	Immunochemical studies of the purified human platelet receptor for the alpha 1 (I)-chain of chick skin collagen.
CA1335791C (en)	1995-06-06	Immunoassay for human chromogranin a